You are here: Industry Insights > Nanomedicine

News List

Nanomedicine to dominate nanobots market in coming years europeanpharmaceuticalreview
May 20, 2021
Novel research shows that nanomedicine and biomedical applications of nanobots will lead the global market between 2021 and 2029.
Nanoform, Aprecia Partner to Advance 3DP Nanomedicines contractpharma
April 23, 2021
Nanoform Finland Plc, a nanoparticle medicine enabling company, and Aprecia, the 3DP (three-dimensional printing) pharmaceutical company, have partnered to explore synergies between their respective technologies in the field of nanoparticle-enabled ...
SNBNCBS develops nanomedicine for better immune power to treat viral infections expresspharma
May 05, 2020
It alters oxidative stress in the body to aid immune cells to perform their natural functions more efficiently.
Evotec, leon-nanodrugs Enter Nanomedicine Pact contractpharma
April 20, 2020
Evotec makes strategic investment in leon by leading the company's Series B funding round.
Chad Mirkin wins Kabiller Prize in nanoscience and nanomedicine biospectrumasia
July 17, 2019
The $250,000 Kabiller Prize is the largest monetary award in the world for outstanding achievement in the field of nanotechnology and its application to medicine and biology.
New machine learning technique rapidly analyzes nanomedicines for cancer immunotherapy worldpharmanews
February 20, 2019
With their ability to treat a wide a variety of diseases, spherical nucleic acids (SNAs) are poised to revolutionize medicine.
Cristal Therapeutics Initiates Phase 2 Clinical Trial of Innovative CriPec® Nanomedicine Drug Candidate in Ovarian Cancer b3cnewswire
November 10, 2018
CPC634 is a new drug modality. It combines CriPec® nanoparticles with docetaxel (Taxotere®), a clinically validated chemotherapy, as its therapeutic payload. This nanomedicine candidate has been designed to enable enhanced tumour accumulation and localise
Blueberry Therapeutics raises £10M funding to develop nanomedicines biospectrumasia
August 20, 2018
Blueberry Therapeutics will use the net proceeds of the Series B Fundraising to fund its development programme for BB2603 for the treatment of onychomycosis and tinea pedis, as well as progressing its earlier stage acne, topical analgesia and atopic derma
Blueberry Therapeutics bags £10M to push dermatology nanomedicines fiercebiotech
August 16, 2018
Athlete’s foot and fungal nail infections aren’t the types of diseases that tend to get investors’ hearts pumping, but that’s not stopping Blueberry Therapeutics. The U.K.-based startup reeled in £10 million ($12.7 million) in series B funding that will,
Precision NanoSystems to host nanomedicines symposium europeanpharmaceuticalreview
July 12, 2017
Precision NanoSystems for its second annual nanomedicines symposium…